Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
b+pharma Belgium from Gent, company number BE0474817869, closed financial year 2025 with a result of € 213,458 after tax. For that financial year b+pharma Belgium recorded a gross margin of € 287,023 and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 203,195 to € 213,458. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 4, 2026.
€ 2.2 million
▲ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 213,458
▲ 5% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -195,236.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 28,008
▼ 35% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 208,786
▲ 42% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 816,898 | € 232,442 | € 283,264 | € 287,023 | ▲ 1% |
| Profit after taxes | € 416,943 | € 194,454 | € 203,195 | € 213,458 | ▲ 5% |
| Equity | € 1,543,657 | € 1,738,111 | € 1,941,305 | € 2,154,764 | ▲ 11% |
| Total debts | € 521,348 | € 214,242 | € 190,334 | € 236,794 | ▲ 24% |
| Cash | € 354,315 | € 0 | - | - | |
| Retained profit | € -806,343 | € -611,889 | € -408,695 | € -195,236 | ▲ € 213,458 |
| Balance sheet total | € 2,065,005 | € 1,952,353 | € 2,131,639 | € 2,391,558 | ▲ 12% |
| Employees (FTE) | 2.4 | 0 | 0 | 0 |
Key figures of b+pharma Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to b+pharma Belgium?
What happened at b+pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AQUITANIA BV stepped down as director. NBB
- CREDOPHAR BV stepped down as director. NBB
- FARMAFENDER BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 213,458 (▲ 5% vs 2024). Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
In short
From € 416,943 profit in 2022 to € 213,458 profit in 2025.
Paid € 257,278 in corporate taxes since 2022.
Best year ever: 2022, with € 416,943 profit.
On average € 340,400 of value added per employee in 2022.
A new publication or filing at b+pharma Belgium? We notify you, reason included.
Follow b+pharma BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Labophar comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
b+pharma BelgiumThe shares are held by Labophar (100%).
Directors
According to the 2025 annual accounts
Director · represented by ANJA IMSCHOOT
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more
since 2022 · until 2028
Director · represented by MARIO DEBEL
Owns 100% via Labophar
since 2022 · until 2028
since 2022 · until 2028
Shareholders
Labophar · holding of CREDOPHAR BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
DGPharma same network
€ 94,120 gross margin · 2024
Ceres Pharma
€ 35.3 million revenue · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0474.817.869
- VAT number
- BE 0474.817.869
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- b+pharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 May 2001
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Handelsbemiddeling in de groothandel in andere specifieke goederen
Groothandel in farmaceutische en medische artikelen
Groothandel in voedsel voor huisdieren
Groothandel in andere voedingsmiddelen, neg
Handelsbemiddeling in de niet-gespecialiseerde groothandel